Indoleamine 2, 3-dioxygenase (IDO) levels in leprosy patients with positive serology
Keywords:
Seropositive leprosy, indoleamine 2, 3-dioxygenase, anti-phenolic glycolipid-1 IgMAbstract
Background  Seropositive leprosy individuals have a tendency to experience a change into leprosy lepromatous type. Previous studies have demonstrated that the activity of indoleamine 2, 3-dioxygenase (IDO) in patients with lepromatous type leprosy is higher than those with tuberculoid type leprosy. However, no study has been available showing how IDO level can be correlated to seropositive subjects. Methods Our observational cross-sectional study was conducted in Brebes, Central Java, Indonesia. Leprosy seropositivity was determined by measuring the level of anti-phenolic glycolipid-1 IgM and IDO level using ELISA. Results Result of The IDO level in seropositive leprosy subjects was higher compared to those who were seronegative (p = 0.048). Conclusion  In the early stage of leprosy infection, a high level of IDO level can already be found; therefore, it can affect immune response and ultimately affecting further course of the disease .ÂReferences
World Health Organization (WHO). Global leprosy update, 2013; reducing diseases burden. Wkly Epidemiol Res. 2014;89:389-400.
Agusni I, Adriaty D, Wahyuni R, Izumi S. Correlation between the sero-positivity level and new case detection rate (NCDR) in some leprosy endemic areas of Indonesia. Jpn J Lepr. 2009;78:140.
Izumi S. Subclinical infection by Mycobacterium leprae. Int J Lepr. 1999;67 (4) (Suppl):S67-71.
Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19:338-81.
de Souza Sales J, Lara FA, Amadeu TP, de Oliveira Fulco T, da Costa Nery JA, Sampaio EP et al. The role of indoleamine 2, 3-dioxygenase in lepromatous leprosy immunosuppression. Clin Exp Immunol. 2011;165:251-63.
Rahfiludin MZ, Pangestuti DR. Phyllanthus niruri extract could improve immunoglobulin-M anti phenolic glycolipid-1 level in seropositive contact of Hansen’s disease patients. J Health Res. 2012;26:55-8.
Murakami Y, Hoshi M, Imamura Y, Arioka Y, Yamamota Y, Saito K. Remarkable role of indoleamine 2,3-dioxygenase and tryptophan metabolites in infectious diseases: potential role in macrophage-mediated inflammatory diseases. Mediators Inflamm. 2013;2013.
Moet FJ, Meima A, Oskam L, Richardus JH. Risk factors for the development of clinical leprosy among contacts, and their relevance for targeted interventions. Lepr Rev. 2004;75:310-32.
Douglas JT, Cellona RV, Fajardo TT Jr, Abalos RM, Balagon MV, Klaster PR. Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. Clin Diag Lab Immunol. 2004;11:897-900.
Becerra A, Warke RV, Xhaja K, Evans B, Evans J, Martin K et al. Increased activity of indoleamine 2, 3-dioxygenase in serum from acutely infected dengue patients linked to gamma interferon antiviral function. J Gen Virol. 2009;90:810-7.
Rahfiludin MZ, Kartasurya MI, Purwaningsih E. The different levels of interferon gamma capacity production on several stages of leprosy. Med J Indones. 2007;16:224-7.
Harden JL, Egilmez NK. Indoleamine 2, 3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest. 2012;41:738-64.
Muller AJ, Heseler K, Schmidt SP, Spekker K, Mackenzie CR, Däubener W. The missing link between indoleamine 2, 3-dioxygenase mediated antibacterial and immunoregulatory effects. J Mol Med. 2009;13:1125-35.
Njau F, Geffers R, Thalmann J, Haller H, Wagner AD. Restriction of Chlamydia pneumoniae replication in human dendritic cell by activation of indoleamine 2, 3-dioxygenase. Microbes Infect. 2009;11:1002-10.
King NJ, Thomas SR. Molecules in focus: indoleamine 2,3-dioxygenase. Int J Biochem Cell Biol. 2007;39:2167-72.
